OKUR

OnKure Therapeutics

• Dow Jones·08/14 17:25

  OnKure Therapeutics Price Target Cut to $14.00/Share From $30.00 by Oppenheimer

• Benzinga·08/14 17:15

  Oppenheimer Reiterates Outperform on OnKure Therapeutics, Lowers Price Target to $14

• TipRanks·08/13 10:36

  OnKure Reprices Underwater Stock Options to Boost Retention

• Seeking Alpha·08/10 23:22

  Recursion Pharmaceuticals: I'm Still Bearish Despite Recent Genentech News

• TipRanks·08/06 03:00

  Wall Street Analysts Are Bullish on Top Healthcare Picks

• TipRanks·08/05 13:00

  Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), OnKure Therapeutics (OKUR) and Alnylam Pharma (ALNY)

• Benzinga·08/04 21:40

  CORRECTION: OnKure Therapeutics Q2 EPS $(0.31) Beats $(0.54) Estimate

• Benzinga·08/04 21:22

  OnKure Therapeutics Announces Registration Of Up To $100M At-The-Market Offering Of Class A Common Stock Through Leerink Partners

• Dow Jones·08/04 20:08

  Press Release: OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

• TipRanks·07/22 12:30

  Fourteen new option listings and one option delisting on July 22nd

• Dow Jones·07/20 16:02

  OnKure Therapeutics Price Target Cut to $21.00/Share From $27.00 by HC Wainwright & Co.

• Dow Jones·07/20 16:02

  OnKure Therapeutics Is Maintained at Buy by HC Wainwright & Co.

• Benzinga·07/20 15:52

  HC Wainwright & Co. Maintains Buy on OnKure Therapeutics, Lowers Price Target to $21

• TipRanks·07/20 12:26

  OnKure Therapeutics price target lowered to $21 from $27 at H.C. Wainwright

• TipRanks·07/16 13:20

  Analysts Conflicted on These Healthcare Names: Fractyl Health, Inc. (GUTS) and OnKure Therapeutics (OKUR)